✦ LIBER ✦

Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

✍ Scribed by Hubert Marotte, Wlodzimierz Maslinski, Pierre Miossec

Book ID: 120707285
Publisher: BioMed Central
Year: 2005
Tongue: English
Weight: 357 KB
Volume: 7
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar1465

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Circulating bioactive TNF in rheumatoid

Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response

✍ H Marotte, P Miossec 📂 Article 📅 2003 🏛 BioMed Central 🌐 English ⚖ 595 KB

Association between the level of circula

Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at −308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor

✍ Hubert Marotte; Béatrice Arnaud; Jennifer Diasparra; Saloua Zrioual; Pierre Mios 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

Repeated therapy with monoclonal antibod

Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

✍ M.J. Elliott; R.N. Maini; M. Feldmann; A. Long-Fox; P. Charles; J.A. Bijl; J.N. 📂 Article 📅 1994 🏛 The Lancet 🌐 English ⚖ 438 KB

Intra-articular infliximab in patients w

Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor

✍ Conti, F; Ceccarelli, F; Priori, R; Iagnocco, A; Signore, A; Valesini, G 📂 Article 📅 2008 🏛 BMJ Publishing Group 🌐 English ⚖ 228 KB

Development of interstitial pneumonia in

Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor α-neutralizing antibody

✍ Shunsuke Mori; Fumiya Imamura; Chikage Kiyofuji; Mineharu Sugimoto 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 326 KB

Individualized monitoring of drug bioava

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b